Leyden Labs Secures €30M To Advance Nasal Spray For Viruses
02 Oct 2025 //
BUSINESSWIRE
Leyden Labs secures €20M EIB Investment for Pandemic Preparedness
03 Jun 2025 //
BUSINESSWIRE
Leyden Labs Confirms Potential of Intranasal Antibody Approach
08 Apr 2025 //
BUSINESSWIRE
Leyden Labs Appoints Jintanat Ananworanich As Chief Medical Officer
12 Sep 2024 //
BUSINESSWIRE
Leyden Labs Licenses Pan-Influenza Antibody from Janssen
18 Jan 2022 //
GLOBENEWSWIRE

Market Place
Sourcing Support